Developer Says CEL-SCI’s L.E.A.P.S. Technology Has Extensive Applications
Special Report FDA & Clinical Trials Calendar
LOS ANGELES, CA–(Marketwire – Oct 19, 2009) – BioMedReports.com, the news
portal which covers Wall Street’s biomedical zone and
delivers monetary and investment comprehension to a
community of rarely sensitive investors, in an exclusive
interview with Daniel H. Zimmerman, Ph.D., of CEL-SCI
Corporation, (NYSE Amex: CVM) is stating which treatments
and applications for the company’s L.E.A.P.S platform
technology might strech far over rheumatoid arthritis and
H1N1.
This past weekend, brand new rheumatoid arthritis interpretation presented
at the American College of Rheumatology’s annual assembly in
Philadelphia by Dr. Zimmerman, indicates which CEL-2000, a
vaccine formed on the company’s L.E.A.P.S. technology, acts
to forestall or retard the permanent hankie repairs caused by
rheumatoid arthritis, but the statistically significant
results might usually be partial of the systematic tour for
technology.
“I’ve been operative on this record for over twenty
years,” explains Zimmerman, “We’ve stranded with it given 1987,
firmly desiring in it, being the key developer for it.
Things have been eventually starting to take off. We’re saying now
that the applications have been as endless as we suspicion that
they would be creatively in the areas of infectious
diseases, autoimmune, maybe even cancer and alternative sorts of
conditions, but we’ve been singular in the resources so we
had to combine on a little key areas, as a result the rheumatoid
arthritis results.”
The finish special inform is accessible right away at
BioMedReports.com:
http://biomedreports.com/articles/most-popular/13801-developer-says-cel-scis-leaps-technology-has-extensive-applications.html
Biotech investors meddlesome in accessing the headlines portal’s
complete database of clinical trials and arriving FDA
decisions can entrance which inform here:
http://biomedreports.com/fda-calendar/fda-calendar.html
About BioMedReports.com
BioMedReports.com is a headlines portal covering the biomedical
news and monetary sector. BioMedReports is not paid,
compensated or in any approach incentivized to inform headlines and
developments about publicly traded companies.
For some-more biomedical zone and investment headlines go to
http://BioMedReports.com
